Previously refused to be acquired, now Liantuo Biotechnology will close its business and delist
海角七号
发表于 2024-2-14 19:02:06
230
0
0
Lian Tuo Biotechnology (LIAN.US), which had previously rejected a tender offer from Concentrate, has now decided to directly close its business and delist.
On February 13th, Liantuo Biotechnology announced that its board of directors had completed a comprehensive strategic review of the company and decided to begin closing its operations. It will then sell its remaining pipeline assets and delist from NASDAQ.
At the same time, the board of directors of Liantuo Biotechnology also announced the distribution of a special dividend of $4.8 per share, totaling approximately $528 million. The company plans to lay off more than 50 employees in the first quarter of 2024, accounting for approximately 50% of the total number of employees.
Liantuo Biotechnology is an innovative pharmaceutical company founded and incubated by Perceive Advisors, a US biopharmaceutical investment fund. It was founded in Shanghai in August 2020 and listed on the NASDAQ market in November of the following year. It has grown rapidly through license in, mainly through cooperation with globally renowned biopharmaceutical companies, to introduce advanced therapies and innovative drugs into China and other major Asian markets. Within less than three years of company registration, the company has obtained nine pipelines in five treatment fields through this licensing model.
However, this licensing and introduction model is not as easy as imagined, as the clinical research and commercial promotion of drugs still require a lot of investment. In addition, the investment in new drug research and development is huge, and there is also uncertainty about whether it can achieve timely returns after being launched.
In recent years, Liantuo Biotechnology has also started a "bad luck" business. In August 2020, Liantuo Biotechnology reached a partnership with Myokardia to acquire the development and commercialization rights of the heart specific myosin allosteric inhibitor Mavacamten in China and other Asian regions for approximately $188 million.
In October 2023, Liantuo Biotechnology sold the development and commercialization rights of Mavacamten in China and other Asian regions to BMS. Liantuo Biotechnology will be entitled to a total consideration of $350 million. Between this one in and one out period, Liantuo Biotechnology made a net profit of over 150 million US dollars.
Biotechnology companies continue to require funding for drug research and development. Currently, Chinese biotechnology companies are facing a capital winter, which poses challenges to refinancing. Since 2024, the actions of enterprises to adjust their business have become more intensive, and there are those who choose to sell themselves. For example, since the end of December 2023, Genxi Biotechnology and Xinruinuo Pharmaceutical have been successively acquired by multinational pharmaceutical companies AstraZeneca and Novartis Xiangzhong; There are also cases of business closures, such as on February 7, 2024, Tianjing Biotechnology announced the divestment of its assets in China; There are also cases of bankruptcy liquidation, such as the news of the bankruptcy liquidation of Boji Biopharmaceutical Technology (Hangzhou) Co., Ltd. on January 23, 2024, which attracted market attention.
As early as October 2023, Liantuo Biotechnology announced that the board of directors had launched a comprehensive strategic evaluation of the company's business development.
Prior to this adjustment by Liantuo Biotechnology, the company had already rejected a tender offer from Concentrate in December last year, which is Tang Capital, an active investor in the biotech field in recent years. At that time, the reason given by Liantuo Biotechnology was "underestimating the value of the company and not in the best interests of Liantuo Biotechnology and its shareholders.".
Konstantin Poukalov, founder and executive chairman of Liantuo Biotechnology, stated that gradually reducing operations is the way to maximize shareholder value in the current biotechnology market.
Liantuo Biotechnology expects that the company will basically complete the comprehensive closure of its business by 2024 and completely dissolve in the first half of 2027.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Yizi International expands its business in China and adds equity investment in Enxi Village
- GlaxoSmithKline China Vaccine Business Leader Confirmed
- IQiyi competes for micro drama business: members can watch for free, 70% of the revenue goes to the content provider
- Joining forces with JD, Gree accelerates channel transformation, ice washing business awaits breakthrough
- Bit Digital completes acquisition of Enovum data center, expanding high-performance computing business
- Eni Group reportedly plans to sell up to 49% stake in its biomethane business
- IBM's generative AI business scale exceeds $3 billion, Q3 revenue increase but still losses
- Pre market forecast: Cloud business growth is expected to slow down, with Microsoft falling 4%; Xiaopeng Motors rises nearly 2%
- FTC plans to investigate anti competitive behavior in Microsoft's cloud computing business
- Selling business in China? Starbucks responds
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏